Solubility / RTP acquisition
Complete acquisition of RTP Pharma
Rich pipeline of over 10 projects
Fenofibrate: lipid-lowering drug Market of over US$500 m in current form Partnered with undisclosed pharmaceutical company
Propofol: improved formulation of anaesthetic/sedative Active component in AstraZeneca’s Dipravan?: 2001 sales of US$465 million Phase IIb in H1 2002: target launch 2005
Complementary client portfolio
Schering Plough, SuperGen, IDEXX, Baxter Healthcare (injectables)
New Paul Capital agreement
US$30 million over next 2 years
Principally to fund clinical development of proprofol, HFA-formoterol Long-acting beta-2 agonist: MDI format Entering human clinical studies H1 2002: target launch in 2004